Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203246 | 0.88 | MTNR1A (0.56) | MTNR1AALOX5NFKB1NFKB2RELA | |
| SCHEMBL5338371 | 0.87 | CYP3A4 (0.43) | MTNR1AALOX5MTNR1B | |
| SCHEMBL5344350 | 0.86 | MTNR1A (0.41) | MTNR1AALOX5 | |
| SCHEMBL5341910 | 0.86 | MTNR1A (0.44) | MTNR1AALOX5 | |
| SCHEMBL6077215 | 0.86 | ALOX5 (0.43) | MTNR1AALOX5 | |
| SCHEMBL7201845 | 0.79 | ALOX5 (0.53) | MTNR1AALOX5NFKB1NFKB2RELA | |
| SCHEMBL6075940 | 0.79 | MTNR1A (0.36) | MTNR1AALOX5 | |
| SCHEMBL7199665 | 0.77 | ALOX5 (0.53) | ALOX5NFKB1NFKB2RELAPTGS1 | |
| SCHEMBL7199661 | 0.77 | ALOX5 (0.50) | ALOX5NFKB1NFKB2RELAPTGS1 | |
| SCHEMBL5225146 | 0.75 | MTNR1A (1.00) | MTNR1AALOX5MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885ALOX5 567/4885NFKB1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.